Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
New Alzheimer’s imaging approval could help unlock Lantheus’ neurology merger payouts
TAUKLARIFY wins FDA approval as Lantheus expands its Alzheimer’s imaging franchise ahead of Curium’s $8bn acquisition and neurology CVR targets.
RESTORE trial could turn NVG-291 into NervGen’s defining spinal cord injury asset
NVG-291 heads into Phase 3 as NervGen deploys its $61m cash runway behind a 150-patient test of hand-function recovery in chronic tetraplegia.
Fate Therapeutics bets on outpatient CAR T as FT819 enters potentially registrational study
FT819 enters a potentially registrational lupus nephritis trial with outpatient dosing as Fate tests whether off-the-shelf CAR T can scale.
Sagimet’s acne strategy enters its biggest test after FDA clears denifanstat Phase 3
FDA clearance sends denifanstat into an 800-patient U.S. Phase 3 as Sagimet deploys its $257.6m cash base. See what the pivotal test means.
Lilly (NYSE: LLY) now gets 65% of H1 revenue from Mounjaro and Zepbound
Mounjaro and Zepbound generated $27.69 billion for Eli Lilly and Company in H1 2026, or almost 65% of total revenue. Excluding the two tirzepatide brands, revenue grew by only about 11%.
Mapi Pharma targets cariprazine lifecycle extension with once-monthly injectable
Mapi’s monthly Cariprazine Depot clears its first safety hurdle as a $3.6bn oral franchise approaches a key 2029 patent transition.
Can a nasal therapy bypass the blood-brain barrier? NEO100’s Phase 2a data offer an early answer
NEO100 posts 48.9% six-month PFS and 26-month median survival, but NeOnc’s $2m cash balance puts funding and FDA strategy in focus.
Eli Lilly (NYSE: LLY) raises 2026 guidance as Mounjaro and Zepbound reshape pharma growth
Eli Lilly raises 2026 guidance as Mounjaro and Zepbound drive 48% Q2 revenue growth. Read how LLY’s GLP-1 scale reshapes Big Pharma.
Theriva targets Phase 2/3 VCN-01 trial after early eye-preservation signal
Theriva plans a VCN-01 Phase 2/3 retinoblastoma trial after early eye-preservation signals, but its $11.3m cash runway raises the stakes.
OPKO Health (Nasdaq: OPK) raises $125m against mazdutide royalties as GLP-1 financing strategy deepens
OPKO Health raises $125 million against mazdutide royalties. Read how the KKR-linked financing reshapes OPK’s GLP-1 capital strategy.